Prolactin may be a promising therapeutic target for myasthenia gravis: Hypothesis and importance

Medical Hypotheses

Volumn 70, Issue 5, 2008, Pages 1017-1020

  Yang, Min ^a   Huang, Lingyun ^b   Liu, Wendong ^c   Sheng, Zhifeng ^a   Xie, Hui ^a   Liao, Eryuan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Hunan Province Geriatric Hospital   (China)

^c Department of Pediatrics   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROLACTIN;

ARTICLE; CD4+ T LYMPHOCYTE; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, BIOLOGICAL; MODELS, THEORETICAL; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; PROLACTIN; RECEPTORS, CHOLINERGIC; T-LYMPHOCYTES;

EID: 40949138821     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.06.044     Document Type: Article

References (45)

1. Pascuzzi R.M. The history of myasthenia gravis. Neurol Clin 12 (1994) 231-242
2. Keesey J.C. "Crisis" in myasthenia gravis: an historical perspective. Muscle Nerve 26 (2002) 1-3
3. Conti-Fine B.M., Milani M., and Kaminski H.J. Myasthenia gravis: past, present, and future. J Clin Invest 116 11 (2006) 2843-2854
4. Wang W., Ostlie N.S., and Conti-Fine B.M. The susceptibility to experimental myasthenia gravis of STAT6-/- and STAT4-/- BALB/c mice suggests a pathogenic role of Th1 cells. J Immunol 172 1 (2004) 97-103
5. Delpy L., Douin-Echinard V., and Garidou L. Estrogen enhances susceptibility to experimental autoimmune myasthenia gravis by promoting type 1-polarized immune responses. J Immunol 175 8 (2005) 5050-5057
6. Hohlfeld R., Toyka K.V., and Tzartos S.J. Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor alpha subunit. Proc Natl Acad Sci USA 84 15 (1987) 5379-5383
7. Bole-Feysot C., Goffin V., and Edery M. Prolactin and its receptor: actions, signal transduction pathways, and phenotypes observed in prolactin receptor knockout mice. Endocr Rev 19 (1998) 225
8. Chuang E., and Molitch M.E. Prolactin and autoimmune diseases in humans. Acta Biomed 78 Suppl. 1 (2007) 255-261
9. Czuwara-Ladykowska J., Sicinska J., and Olszewska M. Prolactin synthesis by lymphocytes from patients with systemic sclerosis. Biomed Pharmacother 60 4 (2006) 152-155
10. Smith P. The effect of hypophysectomy upon the involution of the thymus in the rat. Anat Rec 47 (1930) 119-129
11. Krishnan N., Thellin O., and Buckley D.J. Prolactin suppresses glucocorticoid-induced thymocyte apoptosis in vivo. Endocrinology 144 5 (2003) 2102-2110
12. Russell D.H. New aspects of prolactin and immunity: alymphocyte-derived prolactin-like product and nuclear protein kinase C activation. Trends Pharmacol Sci 10 (1989) 40-44
13. Horseman N.D., and Yu-Lee L.Y. Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin, and hematopoietic cytokines. Endocr Rev 15 (1994) 627-649
14. Matera L. Action of pituitary and lymphocyte prolactin. Neuroimmunomodulation 4 (1997) 171-180
15. Jara L.J., Lavalle C., and Fraga A. Prolactin, immunoregulation, and autoimmune diseases. Sem Arthritis Rheum 20 (1991) 273-284
16. Tsukioka T., Inoue K., and Iwata T. Thymolipoma associated with myasthenia gravis. Gen Thorac Cardiovasc Surg 55 (2007) 26-28
17. Liu W.B., Men L.N., and Chen Z.G. Long-term efficacy of enlarged thymectomy in treatment of myasthenia gravis and relevant influencing factors: study of 410 cases. Zhonghua Yi Xue Za Zhi 86 (2006) 3182-3185
18. Utsugisawa K., Nagane Y., and Suzuki S. Antigen-specific T-cell activation in hyperplastic thymus in myasthenia gravis. Muscle Nerve 36 1 (2007) 100-103
19. Melms A., Luther C., and Stoeckle C. Thymus and myasthenia gravis: antigen processing in the human thymus and the consequences for the generation of autoreactive T cells. Acta Neurol Scand Suppl 183 (2006) 12-13
20. Yoshikawa H., Lambert E.H., and Walser-Kuntz D.R. A 17-Mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis. J Immunol 159 (1997) 1570-1577
21. Sakaguchi S., Sakaguchi N., and Shimizu J. Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182 (2001) 18-32
22. Maloy K.J., and Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2 (2001) 816-822
23. Dieckmann D., Plottner H., and Berchtold S. Ex vivo isolation and characterization of CD4(+) CD25(+) T cells with regulatory properties from human blood. J Exp Med 193 (2001) 1303-1310
24. + T-cell function and inhibit the development of Plasmodium berghei-specific TH1 responses involved in cerebral malaria pathogenesis. Infect Immun 75 (2007) 2275-2282
25. + T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 59 (2004) 198-202
26. + T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 33 (2003) 215-223
27. + regulatory T cells in patients with multiple sclerosis. J Exp Med 199 (2004) 971-979
28. + T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology 116 1 (2005) 134-141
29. Luther C., Poeschel S., and Varga M. Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-associated thymoma. J Neuroimmunol 164 1-2 (2005) 124-128
30. Chuang E., and Molitch M.E. Prolactin and autoimmune diseases in humans. Acta Biomed 78 Suppl. 1 (2007) 255-261
31. Moszkorzova L., Lacinova Z., and Marek J. Hyperprolactinaemia in patients with systemiclupus erythematosus. Clin Exp Rheumatol 20 (2002) 807-812
32. Jara L.J., Gomez-Sanchez C., and Silveira L.H. Hyperprolactinemia in systemiclupus erythematosus: association with disease activity. Am J Med Sci 303 (1992) 222-226
33. Jacobi A.M., Rohde W., and Ventz M. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus 10 (2001) 554-561
34. Vera-Lastra O., Mendez C., and Jara L.J. Correlation of prolactin serum concentrations with clinical activity and remissionin patients with systemic lupus erythematosus. Effect of conventional treatment. J Rheumatol 30 (2003) 2140-2146
35. Alvarez-Nemegyei J., Cobarrubias-Cobos A., and Escalante-Triay F. Bromocriptinein systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Lupus 7 (1998) 414-419
36. Nagy E., Berczi I., and Friesen H.G. Regulation of immunity in rats by lactogenic and growth hormones. Acta Endocrinol (Copenh) 102 (1983) 351-357
37. Berczi I., Nagy E., and de Toledo S. Pituitary hormones regulate c-myc and DNA synthesis in lymphoid tissue. J Immunol 146 (1991) 2201-2206
38. Carreño P.C., Sacedón R., and Jiménez E. Prolactin affects both survival and differentiation of T-cell progenitors. J Neuroimmunol 160 1-2 (2005) 135-145
39. Gaufo G.O., and Diamond M.C. Prolactin increases CD4/CD8 cell ratio in thymus-grafted congenitally athymic nude mice. Proc Natl Acad Sci USA 93 (1996) 4165-4169
40. Yamanouchi J., Rainbow D., and Serra P. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 39 3 (2007) 329-337
41. Zheng S.G., Wang J., and Wang P. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 178 4 (2007) 2018-2027
42. Bayer A.L., Yu A., and Malek T.R. Function of the IL-2R for thymic and peripheral CD4+CD25+Foxp3+ T regulatory cells. J Immunol 178 7 (2007) 4062-4071
43. Matera L., Cutufia M., and Geuna M. Prolactin is an autocrine growth factor for the Jurkat human T-leukemic cell line. J Neuroimmunol 79 1 (1997) 12-21
44. Tsinzerling N., Pirskanen R., and Matell G. Raised prolactin levels in myasthenia gravis: two case reports and a study of two patient populations. Acta Neurol Scand 114 5 (2006) 346-349
45. Lysenko G.I., Shevniuk M.M., and Shatrova K.M. Hypophyseal-adreno-gonadal system function in myasthenia patients with tumorous and nontumorous pathology of the thymus. Lik Sprava 6 (1998) 79-82